June 5, 2024 – Page 9 – Goldea Capital

Fortuna Announces Offering of Convertible Senior Notes

Written by Customer Service on June 5, 2024. Posted in Public Companies.

VANCOUVER, British Columbia, June 05, 2024 (GLOBE NEWSWIRE) — Fortuna Silver Mines Inc. (TSX: FVI) (NYSE: FSM) (“Fortuna” or the “Company”) announces that it is offering convertible senior notes due 2029 (the “Notes”) in an aggregate principal amount of US$150 million (the “Offering”). The Company expects to grant the initial purchasers of the Notes an option for a period of 15 days to purchase up to an additional US$22.5 million aggregate principal amount of Notes. The Company intends to use the net proceeds from the Offering to repay bank indebtedness, to fund working capital requirements, for general corporate purposes and to fund the repayment of its existing 4.65% senior subordinated unsecured convertible debentures, to the extent that such debentures are not converted into shares prior to the redemption date. Immediately...

Eldorado Gold Announces Election of Directors and Voting Results from Annual Meeting of Shareholders

Written by Customer Service on June 5, 2024. Posted in Public Companies.

VANCOUVER, British Columbia, June 05, 2024 (GLOBE NEWSWIRE) — Eldorado Gold Corporation (“Eldorado” or “the Company”) is pleased to announce that all director nominees, as listed in the Management Proxy Circular dated April 16, 2024, were elected as directors of Eldorado at the Company’s Annual Meeting of Shareholders (the “Meeting”) held on June 4, 2024. “On behalf of the Board, we would like to thank our shareholders for their continued support as Eldorado Gold continues to advance construction at Skouries, and remains focused on delivering value drivers at our existing operations,” said Steven Reid, Chair of Eldorado Gold’s Board of Directors. “Further, we would like to thank Pamela Gibson, who, as part of our Board succession plan, did not stand for re-election this year. Her commitment, tireless effort and...

Y-mAbs Deepens Radiopharmaceutical Leadership with Appointment of Norman LaFrance, M.D. as Chief Development Officer

Written by Customer Service on June 5, 2024. Posted in Public Companies.

NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Norman LaFrance, M.D. as Chief Development Officer. “We are thrilled to welcome Dr. LaFrance to Y-mAbs,” Mike Rossi, President and Chief Executive Officer. “Norman has an impressive track record in the research, development and commercialization of radiotherapeutics, molecular imaging, diagnostic and therapeutic products. With his deep expertise in developing Targeted Radiotherapies and radiopharmaceuticals, Norman will play a key role in the further advancement of our novel Self-Assembly DisAssembly...

Ocean Biomedical (NASDAQ: OCEA) Congratulates Joint Venture Partner, Virion Therapeutics, on Positive Immunogenicity Results from Their Lead Checkpoint Modifier-Containing Immunotherapy, VRON-0200, for HBV Functional Cure, at EASL 2024

Written by Customer Service on June 5, 2024. Posted in Public Companies.

Providence, RI, June 05, 2024 (GLOBE NEWSWIRE) — Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development of compelling discoveries from top research scientists, today congratulates its JV partner Virion Therapeutics, LLC, a clinical-stage biotechnology company developing novel T cell-based immunotherapies, on its late breaker presentation highlighting the first-ever human immunogenicity data from its novel checkpoint modifier immunotherapy for HBV functional cure (VRON-0200), at the EASL 2024 Congress (The European Association for the Study of the Liver), taking place in Milan, Italy from June 5 – 8. The late breaker Phase 1b data presented today, (for more information, go to VirionTx.com), which includes Virion’s first checkpoint modifier, glycoprotein D (gD), demonstrated that VRON-0200...

YieldMax™ ETFs Announces Monthly Distributions on MSTY (106.33%), NVDY (101.82%), CONY (84.85%), YBIT (81.00%), AIYY (78.90%) and Others

Written by Customer Service on June 5, 2024. Posted in Dividend Reports And Estimates.

CHICAGO, MILWAUKEE and NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) — YieldMax™ today announced monthly distributions for the following YieldMax™ ETFs: ETF Ticker1 ETF Name Reference Asset Distribution per Share Distribution Rate2 30-Day SEC Yield3 Ex-Date* Record Date* Payment Date TSLY YieldMax™ TSLA Option Income Strategy ETF TSLA $0.6448 51.06% 4.20% 6/6/2024 6/6/2024 6/7/2024 OARK YieldMax™ Innovation Option Income Strategy ETF ARKK $0.4003 43.76% 4.76% 6/6/2024 6/6/2024 6/7/2024 APLY YieldMax™ AAPL Option Income Strategy ETF AAPL $0.4043 27.40% 4.01% 6/6/2024 6/6/2024 6/7/2024 NVDY YieldMax™ NVDA Option Income Strategy ETF NVDA $2.5630 101.82% 4.00% 6/6/2024 6/6/2024 6/7/2024 AMZY YieldMax™ AMZN Option Income Strategy ETF AMZN $0.9541 50.74% 4.32% 6/6/2024 6/6/2024 6/7/2024 FBY YieldMax™...

Endeavour Announces Total Voting Rights

Written by Customer Service on June 5, 2024. Posted in Public Companies.

ENDEAVOUR ANNOUNCES TOTAL VOTING RIGHTS London, 05 June 2024 – Endeavour Mining plc (LSE:EDV, TSX:EDV) (“the Company”) The following notification is made in accordance with the UK Financial Conduct Authority’s (“FCA”) Disclosure Guidance and Transparency Rule 5.6. As at close of business on 31 May 2024, the issued ordinary share capital of the Company was 244,931,013 ordinary shares of US$0.01 each. There were 34,980 ordinary shares held in treasury pending cancellation and therefore the total number of voting rights in the Company was 244,896,033. This figure for the total number of voting rights may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA’s Disclosure...

Lands’ End Announces First Quarter 2024 Results

Written by Customer Service on June 5, 2024. Posted in Earnings Releases And Operating Results.

DODGEVILLE, Wis, June 05, 2024 (GLOBE NEWSWIRE) — Lands’ End, Inc. (NASDAQ: LE) today announced financial results for the first quarter ended May 3, 2024. Andrew McLean, Chief Executive Officer, stated, “Our performance in the first quarter continued the considerable momentum we generated in 2023 and resulted in an increase in our Gross Merchandise Value, an increase in gross profit dollars and significant gross margin expansion. Our value creation strategy, centered around Lands’ End being the innovative, asset-light solutions-based brand that’s ready for life’s every journey, is yielding the operational and financial results we’re targeting and positioning us well to further build the brand and grow our loyal customer base.” First Quarter Financial Highlights Gross Merchandise Value (“GMV”) is total order value of all merchandise...

Mesa Labs Announces Fourth Quarter and Full Fiscal Year 2024 Results

Written by Customer Service on June 5, 2024. Posted in Earnings Releases And Operating Results.

LAKEWOOD, Colo., June 05, 2024 (GLOBE NEWSWIRE) — Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its fourth fiscal quarter (“4Q24”) and fiscal year (“FY24”) ended March 31, 2024 (amounts in thousands). Fourth quarter FY24 compared to fourth quarter FY23: Revenues increased 6% and increased 10.2% vs 3Q24 Non-GAAP core organic revenues1 decreased 3.5% Operating (loss) was $(271,284) which included a $274,533 non-cash impairment charge Non-GAAP adjusted operating income excluding unusual items2 increased 26.3% and was 25.4% as a percentage of revenues Full FY24 compared to full FY23: Revenues decreased 1.3% Non-GAAP core organic revenues decreased 5.4% Operating (loss) was $(272,075) which included...

Affimed to Report First Quarter 2024 Financial Results & Corporate Update on June 12, 2024

Written by Customer Service on June 5, 2024. Posted in Public Companies.

MANNHEIM, Germany, June 05, 2024 (GLOBE NEWSWIRE) — Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release first quarter 2024 results and corporate update on Wednesday, June 12, 2024. The Company will host a conference call at 8:30 a.m. EDT / 14:30 CET. The conference call will be available via phone and webcast. The live audio webcast of the call will be available in the “Webcasts” section on the “Investors” page of the Affimed website at https://www.affimed.com/investors/webcasts-and-corporate-presentation/. To access the call by phone, please use link https://register.vevent.com/register/BId697f70815a8448d80b68becf533be98, and you will be provided with dial-in details and a pin number. Note: To avoid delays,...

THOR Industries Announces Third Quarter Fiscal 2024 Results

Written by Customer Service on June 5, 2024. Posted in Public Companies.

CONTINUES DISCIPLINED APPROACH IN SOFT RETAIL ENVIRONMENT, ADJUSTS GUIDANCE TO REFLECT CURRENT MARKET CONDITIONS Fiscal Third Quarter 2024 Highlights Consolidated net sales for the third quarter were $2.80 billion. Consolidated gross profit margin for the third quarter was 15.1%. Net income attributable to THOR Industries, Inc. and diluted earnings per share for the third quarter of fiscal 2024 were $114.5 million and $2.13, respectively. The Company revised its full-year fiscal 2024 guidance to a consolidated net sales range of $9.8 billion to $10.1 billion, gross margin range of 13.75% to 14.0% and diluted earnings per share range of $4.50 to $4.75. ELKHART, Ind., June 05, 2024 (GLOBE NEWSWIRE) — THOR Industries, Inc. (NYSE: THO) today announced financial results for its third fiscal quarter ended April 30, 2024. “We are proud...

Day: June 5, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice